Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Proof of Concept Clinical Trial to Investigate OTL-300 in Transfusion-Dependent Beta-Thalassemia Patients

Next Previous
Trial Profile

A Proof of Concept Clinical Trial to Investigate OTL-300 in Transfusion-Dependent Beta-Thalassemia Patients

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs OTL 300 (Primary) ; Thiotepa; Treosulfan
  • Indications Beta-thalassaemia
  • Focus Adverse reactions; Proof of concept; Therapeutic Use

    • Most Recent Events

    • 29 Apr 2019 According to the Orchard Therapeutics media release, data from this trial will be featured in an oral presentation at the 22nd American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in Washington, D.C. The presentation will report the updated safety and efficacy results of OTL-300 in nine TDT patients.
    • 29 Apr 2019 Results published in the Orchard Therapeutics media release.
    • 15 Apr 2019 According to the Orchard Therapeutics media release, data from this trial will be published online in an abstract via the American Society of Gene & Cell Therapy website and full data set will be featured in an oral presentation at the 22nd ASGCT Annual Meeting 2019.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top